KeyBanc upgraded Cryoport (CYRX) to Overweight from Sector Weight with a $15 price target following the Q2 beat. The firm believes the cell and gene therapy market is gaining momentum as FDA approved therapies, particularly CAR-Ts, emerge as a significant growth driver. The analyst now has visibility into more consistent results going forward for Cryoport.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYRX: